Related Experiment Video

Updated: Jul 19, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion

Yigong Fu1, Radoslaw Zagozdzon, Ron Avraham

  • 1Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

International Journal of Oncology
|November 8, 2006
PubMed

Insights

This study shows that CHK (a protein) is expressed in pancreatic cancer and negatively regulates ErbB-2 and Lyn kinase signaling. CHK inhibits pancreatic cancer cell growth and invasion, suggesting a potential therapeutic role.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • Pancreatic cancer signaling pathways involve Ras oncogene mutations and ErbB-2/Src-family kinase overexpression.
  • Understanding novel regulators of these pathways is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the expression and function of CHK in pancreatic cancer.
  • To determine CHK's role in regulating ErbB-2 and Lyn kinase signaling.

Main Methods:

  • Analysis of CHK expression in human pancreatic cancer tissues.
  • Co-immunoprecipitation to assess CHK association with ErbB-2 in PANC-1 cells.
  • Assessment of CHK's effect on Lyn kinase activity, cell growth, and invasion.

Main Results:

  • CHK is expressed in human pancreatic cancer tissues.
  • CHK binds to ErbB-2 via its SH2 domain in PANC-1 cells.
  • CHK downregulates Lyn kinase activity and inhibits EGF-stimulated PANC-1 cell growth and invasion.

Conclusions:

  • CHK acts as a negative regulator of ErbB-2 and Lyn kinase signaling in pancreatic cancer.
  • CHK demonstrates potential as a therapeutic target for inhibiting pancreatic cancer progression.

More Related Videos

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...